NASDAQ · MIRM
Healthcare · Biotechnology
$85.74
Up+$0.74 (+0.87%)
Updated Nov 3, 2026, 7:59 AM
SID Score
4.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance · MIRM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
MIRM closed at $85.74 after 21 trading sessions, up 5.29% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $85.55 | $86.52 | $83.685 | $85.74 | 537.46K |
| Oct 30, 2026 | $85.21 | $87.49 | $84.115 | $85.00 | 673.43K |
| Oct 29, 2026 | $86.72 | $88.51 | $84.66 | $86.39 | 591.32K |
| Oct 28, 2026 | $85.00 | $86.63 | $84.28 | $85.81 | 535.23K |
| Oct 27, 2026 | $83.27 | $85.62 | $82.175 | $85.56 | 563.28K |
| Oct 26, 2026 | $81.76 | $83.47 | $81.16 | $83.27 | 429.98K |
| Oct 23, 2026 | $82.39 | $83.00 | $80.24 | $80.39 | 788.22K |
| Oct 22, 2026 | $83.26 | $84.855 | $82.58 | $83.10 | 420.91K |
| Oct 21, 2026 | $85.16 | $85.84 | $82.86 | $83.44 | 646.89K |
| Oct 20, 2026 | $82.75 | $85.55 | $82.315 | $85.07 | 633.3K |
| Oct 19, 2026 | $80.90 | $82.89 | $80.345 | $82.24 | 417.9K |
| Oct 16, 2026 | $82.48 | $82.48 | $79.64 | $80.14 | 462.95K |
| Oct 15, 2026 | $82.10 | $83.48 | $81.00 | $82.39 | 605.25K |
| Oct 14, 2026 | $78.41 | $81.905 | $78.35 | $79.96 | 975.12K |
| Oct 13, 2026 | $86.06 | $87.00 | $79.51 | $79.62 | 762.63K |
| Oct 12, 2026 | $87.22 | $88.31 | $81.95 | $86.06 | 1.21M |
| Oct 9, 2026 | $81.01 | $87.79 | $81.01 | $86.01 | 1.14M |
| Oct 8, 2026 | $80.31 | $82.20 | $78.63 | $81.35 | 664.3K |
| Oct 7, 2026 | $78.79 | $83.1325 | $78.39 | $80.64 | 1.02M |
| Oct 6, 2026 | $81.94 | $81.94 | $77.78 | $79.25 | 1.15M |
| Oct 5, 2026 | $83.30 | $83.35 | $81.23 | $81.43 | 980.14K |
The latest Smart Investors Daily articles mentioning MIRM.
Company
Market Activity
Research & News
MIRM research
Company profile and research snapshot.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | TD Cowen | Buy | — |
| Oct 15, 2026 | Stifel | Buy | — |
| Oct 13, 2026 | Morgan Stanley | Overweight | — |
| Oct 13, 2026 | Evercore ISI Group | Outperform | — |
| Oct 12, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 2, 2026
FOSTER CITY, Calif., November 02, 2026--Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD’s The Liver Meeting® 2026
Yahoo · Oct 31, 2026
Is ANAB a good stock to buy? We came across a bullish thesis on AnaptysBio, Inc. on TripleS Special Situations’s Substack. Since the thesis was published on June 15th, ANAB shares have pulled back as uncertainty over its GSK dispute and scrutiny of earnings boosted by a one-time tax benefit weighed on sentiment, creating a near-term hurdle […]
Yahoo · Oct 28, 2026
Recursion Pharmaceuticals (RXRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 28, 2026
Mirum Pharmaceuticals has delivered a very strong multi year share price run, and with the stock recently closing at US$85.56 the live question is whether that level can be explained by what the business is generating in sales today. Over the last 5 years, Mirum Pharmaceuticals has returned about 417.3%, which puts a lot of pressure on its current sales to justify where the stock now trades. Positive results from the PROGRESS study for ATEBRIOZ in pediatric FOP may support expectations for...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MIRM.
